Revaccination of individuals with cardiac adverse events following COVID-19 vaccination: A Canadian Immunization Research Network study
Vaccine·
- DOI
- 10.1016/j.vaccine.2025.128016
- PMID
- 41317434
- PMCID
- —
- OpenAlex
- W4416776940
- Study type
- Journal article
- Publisher
- Elsevier BV
- Article type
- journal-article
- Integrity
- current
Why this research matters now
Findings inform clinical guidance on revaccination after cardiac AEFIs, suggesting revaccination may be considered for chest pain not meeting myocarditis criteria while indicating caution for adults with prior myopericarditis.
Structured evidence summary
Research question
The study examined outcomes of COVID-19 revaccination among individuals previously assessed for cardiac adverse events following immunization (AEFI), where safety data were noted as lacking.
Study design
A multi-site analysis of the Special Immunization Clinic Network database (twelve sites) using Brighton Collaboration Case Definitions, with physician-based revaccination recommendations and follow-up to 42 days post-revaccination.
Population and setting
114 consented participants (enrolled January 1, 2021 – February 23, 2023) across twelve Canadian sites, classified as myocarditis, myopericarditis, pericarditis, or chest pain/other cardiac diagnosis.
Main findings
Of 71 participants requiring further doses, 27 (38.0%) were recommended for revaccination and 16 were revaccinated. Four adults experienced recurrent symptoms after revaccination, including one hospitalization for previous myopericarditis.
Public-health relevance
Findings inform clinical guidance on revaccination after cardiac AEFIs, suggesting revaccination may be considered for chest pain not meeting myocarditis criteria while indicating caution for adults with prior myopericarditis.
Important limitations
This summary is limited to the supplied single-article abstract/metadata and requires the original paper for decision-grade interpretation; the abstract does not explicitly state additional limitations such as small revaccinated subgroup size or lack of a control group.
GIDS interpretation
The article is catalogued under SARS/COVID-19 and vaccine safety topics, providing discoverable evidence on revaccination safety after cardiac AEFIs; no link to a live surveillance signal is established.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 10 auditable classifier relationships to diseases, places, topics, and study design.